Company Filing History:
1 out of 21 
1 out of 318 
Years Active: 2000
Title: Mark Abel: Innovator in Fungal Infection Treatment
Introduction: Mark Abel is an accomplished inventor based in Edmonton, Canada, recognized for his contributions to pharmaceutical innovation. With a focus on therapeutic agents aimed at treating fungal infections, his work has made a significant impact in the field of medicine.
Latest Patents: Mark Abel holds a patent related to Triazoles as therapeutic agents for fungal infections. His patent outlines a compound of formula I, or its optical isomer or pharmaceutically acceptable salt, demonstrating its efficacy in treating or preventing fungal infections. This patent is a crucial addition to the arsenal of treatments available for combating such infections.
Career Highlights: Throughout his career, Mark has worked with notable companies such as Synphar Laboratories, Inc. and Taiho Pharmaceutical Company Limited. His roles in these organizations have contributed to the development and refinement of pharmaceutical applications related to his patented inventions.
Collaborations: Mark's collaborative spirit is evident in his work alongside esteemed colleagues, including Mohsen Daneshtalab and Yadagiri Bathini. Together, they have driven forward research and innovation, enhancing the potential for effective treatments in the medical community.
Conclusion: Mark Abel's dedication to innovation in the field of pharmaceuticals exemplifies the importance of research and development in overcoming medical challenges. His patented work on Triazoles showcases his contributions to tackling fungal infections, reaffirming his position as a notable inventor in the industry.